Ashraf Saifullah
Research Subjects
Research Interests
Ashraf Saifullah has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Anupama Mehta
Department of Blood and Marrow Transplantation
1 shared publication- Bakulesh Khamar
Research & Development, Cadila Pharmaceuticals Ltd., Ahmedabad 382225, India
1 shared publication - Dhanir Tailor
Center for Experimental Therapeutics, Oregon Health and Science University, Portland, OR 97239, USA
1 shared publication Gitali Bhagawati
Department of Pathology and Microbiology, Dharamshila Narayana Super-speciality Hospital
1 shared publicationHemamalini Aiyer
Department of Pathology and Microbiology, Dharamshila Narayana Super-speciality Hospital
1 shared publication- Jaganath Arunachalam
Cellular Therapy and Immunology, Manashi Chakrabarti Foundation
1 shared publication
Latest Publications
- Open Access
Augmenting vaccine efficacy against delta variant with ‘Mycobacterium- w ’ mediated modulation of NK-ADCC and TLR-MYD88 pathways
SUMMARY: Mycobacterium-w (Mw), was shown to boost adaptive natural killer (ANK) cells and protect against COVID-19 during the first wave of the pandemic. As a follow-up of the trial, 50 healthcare workers (HCW) who had received Mw in September 2020 and subsequently received at least one dose of ChAdOx1 nCoV-19 vaccine (Mw+ChAdOx1 group) were monitored for symptomatic COVID-19, during a major outbreak with the delta variant of SARS-CoV-2 (April-June, 2021), along with 201 HCW receiving both doses of the vaccine without Mw (ChAdOx1 group). Despite 48% having received just a single dose of the vaccine in Mw+ChAdOx1 group, only 2 had mild COVID-19, compared to 36 infections in the ChAdOx1 group (HR-0.46, p=0.009). Transcriptomic studies revealed an enhanced adaptive NK cell-dependent ADCC in the Mw+ChAdOx1 group, along with downregulation of TLR2-MYD88 pathway and concomitant attenuation of downstream inflammatory pathways. This might have resulted in robust protection during the pandemic with the delta variant.
Open AccessAugmenting vaccine efficacy against delta variant with ‘Mycobacterium- w ’ mediated modulation of NK-ADCC and TLR-MYD88 pathways
SUMMARY: Mycobacterium-w (Mw), was shown to boost adaptive natural killer (ANK) cells and protect against COVID-19 during the first wave of the pandemic. As a follow-up of the trial, 50 healthcare workers (HCW) who had received Mw in September 2020 and subsequently received at least one dose of ChAdOx1 nCoV-19 vaccine (Mw+ChAdOx1 group) were monitored for symptomatic COVID-19, during a major outbreak with the delta variant of SARS-CoV-2 (April-June, 2021), along with 201 HCW receiving both doses of the vaccine without Mw (ChAdOx1 group). Despite 48% having received just a single dose of the vaccine in Mw+ChAdOx1 group, only 2 had mild COVID-19, compared to 36 infections in the ChAdOx1 group (HR-0.46, p=0.009). Transcriptomic studies revealed an enhanced adaptive NK cell-dependent ADCC in the Mw+ChAdOx1 group, along with downregulation of TLR2-MYD88 pathway and concomitant attenuation of downstream inflammatory pathways. This might have resulted in robust protection during the pandemic with the delta variant.